Probatebeta
Target

HTR2C

5-hydroxytryptamine receptor 2C

As of the edition of 20 October 2026, HTR2C (5-hydroxytryptamine receptor 2C, UniProt P28335) has 24 drugs tested at it and 20 companies on the list, 4 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P28335
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
8
Disease areas
Mental health; Nervous system; Nutrition and metabolism; Cancer; Chemically induced; Hormones; Inherited and neonatal; Lungs and airways
Registered trials of its drugs
563

Drugs at this target

StatusCount
Marketed13
Active1
Went quiet4
Stopped2
Withdrawn from market3
Status not established1
Total24
DrugStatusFurthest phaseUS protection
OlanzapineMarketedPhase 4none listed
ZiprasidoneMarketedPhase 4none listed
MirtazapineMarketedPhase 4none listed
LorcaserinWithdrawn from marketPhase 4none listed
TrazodoneMarketedPhase 4Ends 2029
FenfluramineMarketedPhase 4Ends 2036
AgomelatineMarketedPhase 4none listed
SertindoleWithdrawn from marketPhase 4none listed
EsmirtazapineStoppedPhase 3none listed
VabicaserinWent quietPhase 2none listed
BMB-101ActivePhase 2none listed
TrimipramineMarketedPhase 4none listed

12 of 24 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A4
Route B5
Engaged2
Undetermined9
Total on the list20
Three companies on route A or B, with the route only
CompanyRoute
EisaiRoute A
Merck & Co.Route B
Eli LillyRoute B

The other 17 companies at HTR2C

In the product

20 companies in all; 17 are not named here, and no score is.

See the 20 companies at HTR2C, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at HTR2C

Other targets in mental health

Companies holding approvals at HTR2C